

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2023/2024 influenza season**

as of December 19, 2023

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	0	0	0	0	0	48 (100%)	2 (1.1%)	0	0	0	0	73 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	109	189	189	63	63	48	174	72	72	72	72	73	2	2	2	2	2
<b>Number of viruses reported</b>	588						1,202						27				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.